S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61
S&P 500   4,701.21
DOW   35,754.75
QQQ   399.61

Ingevity Stock Forecast, Price & News

+0.87 (+1.15%)
(As of 12/8/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
155,789 shs
Average Volume
225,038 shs
Market Capitalization
$3.00 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive NGVT News and Ratings via Email

Sign-up to receive the latest news and ratings for Ingevity and its competitors with MarketBeat's FREE daily newsletter.

Ingevity logo

About Ingevity

Ingevity Corp. engages in the manufacture of specialty chemicals and carbon materials. It operates through the following segments: Performance Chemicals and Performance Materials. The Performance Materials segment consists of automotive technologies and process purifications product families. Automotive technologies produces automotive carbon products used in gasoline vapor emission control systems in cars, trucks, motorcycles and boats. Process purifications produce a number of activated carbon products for food, water, beverage and chemical purification applications. The Performance Chemicals segment primarily addresses applications in three product families: pavement technologies, oilfield technologies, and industrial specialties. The company was founded on March 27, 2015 and is headquartered in North Charleston, SC.


See More Headlines

Industry, Sector and Symbol

Chemicals & allied products
Previous Symbol
Year Founded

Sales & Book Value

Annual Sales
$1.22 billion
Cash Flow
$7.69 per share
Book Value
$16.41 per share


Net Income
$181.40 million
Pretax Margin




Free Float
Market Cap
$3.00 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

1.94 out of 5 stars

Basic Materials Sector

135th out of 223 stocks

Chemicals & Allied Products Industry

15th out of 20 stocks

Analyst Opinion: 2.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Ingevity (NYSE:NGVT) Frequently Asked Questions

Is Ingevity a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Ingevity stock.
View analyst ratings for Ingevity
or view top-rated stocks.

How has Ingevity's stock price been impacted by Coronavirus?

Ingevity's stock was trading at $38.80 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, NGVT shares have increased by 96.8% and is now trading at $76.36.
View which stocks have been most impacted by COVID-19

When is Ingevity's next earnings date?

Ingevity is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Ingevity

How were Ingevity's earnings last quarter?

Ingevity Co. (NYSE:NGVT) posted its earnings results on Wednesday, October, 27th. The company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.08. The business had revenue of $376.80 million for the quarter, compared to analysts' expectations of $354.29 million. Ingevity had a trailing twelve-month return on equity of 35.46% and a net margin of 10.11%. The firm's quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.79 EPS.
View Ingevity's earnings history

What guidance has Ingevity issued on next quarter's earnings?

Ingevity issued an update on its FY 2021 earnings guidance on Wednesday, November, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $1.32 billion-$1.36 billion, compared to the consensus revenue estimate of $1.35 billion.

What price target have analysts set for NGVT?

4 Wall Street analysts have issued 1-year price objectives for Ingevity's stock. Their forecasts range from $81.00 to $112.00. On average, they expect Ingevity's share price to reach $93.00 in the next twelve months. This suggests a possible upside of 21.8% from the stock's current price.
View analysts' price targets for Ingevity
or view top-rated stocks among Wall Street analysts.

Who are Ingevity's key executives?

Ingevity's management team includes the following people:
  • John C. Fortson, President, CEO, Treasurer & Director
  • Marty Heyne, Senior Vice President-Operations
  • Mary Dean Hall, Chief Financial Officer & Executive Vice President
  • Mike Smith, EVP, President-Strategy & Business Development
  • Stacy Lancaster Cozad, Secretary, Vice President & General Counsel

What is John Fortson's approval rating as Ingevity's CEO?

2 employees have rated Ingevity CEO John Fortson on Glassdoor.com. John Fortson has an approval rating of 100% among Ingevity's employees. This puts John Fortson in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include Pfizer (PFE), AbbVie (ABBV), General Electric (GE), Verizon Communications (VZ), WestRock (WRK), Abbott Laboratories (ABT), Boeing (BA), Costco Wholesale (COST), Dominion Energy (D) and Johnson & Johnson (JNJ).

What is Ingevity's stock symbol?

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Who are Ingevity's major shareholders?

Ingevity's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.82%), Boston Partners (5.20%), Wellington Management Group LLP (2.96%), LSV Asset Management (2.77%), Broad Bay Capital Management LP (2.39%) and Ardevora Asset Management LLP (1.95%). Company insiders that own Ingevity stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, Richard B Kelson and Stuart Edward Jr Woodcock.
View institutional ownership trends for Ingevity

Which major investors are selling Ingevity stock?

NGVT stock was sold by a variety of institutional investors in the last quarter, including Boston Partners, BlackRock Inc., Primecap Management Co. CA, Broad Bay Capital Management LP, Two Sigma Advisers LP, Two Sigma Investments LP, Royal Bank of Canada, and Invesco Ltd..
View insider buying and selling activity for Ingevity
or view top insider-selling stocks.

Which major investors are buying Ingevity stock?

NGVT stock was acquired by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Millennium Management LLC, Ararat Capital Management LP, Renaissance Technologies LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund, BNP Paribas Asset Management Holding S.A., and Putnam Investments LLC. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, and Richard B Kelson.
View insider buying and selling activity for Ingevity
or or view top insider-buying stocks.

How do I buy shares of Ingevity?

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ingevity's stock price today?

One share of NGVT stock can currently be purchased for approximately $76.36.

How much money does Ingevity make?

Ingevity has a market capitalization of $3.00 billion and generates $1.22 billion in revenue each year. The company earns $181.40 million in net income (profit) each year or $3.42 on an earnings per share basis.

How many employees does Ingevity have?

Ingevity employs 1,750 workers across the globe.

What is Ingevity's official website?

The official website for Ingevity is www.ingevity.com.

Where are Ingevity's headquarters?

How can I contact Ingevity?

Ingevity's mailing address is 4920 O`Hear Avenue Suite 400, North Charleston SC, 29406. The company can be reached via phone at (844) 643-8489, via email at [email protected], or via fax at 843-740-8165.

This page was last updated on 12/9/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.